奥拉帕利单药维持治疗新诊断晚期BRCA基因突变上皮性卵巢癌、输卵管癌或原发性腹膜癌患者的药物经济学评价
陈斌斌,范长生
奥拉帕利单药维持治疗新诊断晚期BRCA基因突变上皮性卵巢癌、输卵管癌或原发性腹膜癌患者的药物经济学评价
Pharmacoeconomic evaluation of olaparib monotherapy in patients with newly diagnosed advanced BRCA mutation epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer
{{custom_ref.label}} |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
/
〈 | 〉 |